Medical genetics
Gaucher disease: the approved drugs compared for prescribers
Cerezyme side by side on what each first fill waits on, what the label requires you to monitor and what an insurer asks to see, with FDA decisions, label changes and open trials for Gaucher disease.
When to suspect Gaucher disease and what to test →The Gaucher disease prescribing guide
One page per drug with the dispensing gate, prior authorization documentation, dosing, monitoring and interactions, each line sourced.
The drugs side by side
Each cell is a summary of that drug's prescribing guide, which carries the full detail and a source on every line. Insurer thresholds are one public policy shown as an example; plans differ.
| Cerezymeimiglucerase | |
|---|---|
| Label dated | August 27, 2026 |
| Starting dose | 2.5 units/kg three times a week to 60 units/kg once every 2 weeks IV; titrate to disease severity and therapeutic goals. |
| Dispensing gate | No REMS. Boxed warning: initiate in a healthcare setting with monitoring and CPR equipment. Prior authorization and a site of care before the first infusion |
| Required monitoring | Supervised infusion with anaphylaxis readiness at every dose; premedicate after prior hypersensitivity; consider periodic IgG antibody monitoring during the first year; disease tests at the physician's discretion |
| Example PA threshold | Cigna example: documented deficient beta-glucocerebrosidase activity in leukocytes or fibroblasts, or biallelic pathogenic GBA variants; not for neurological manifestations; specialist prescriber; up to 60 U/kg no more than 3 times a week; no concurrent Gaucher therapy |
| Support line | CareConnect Case Managers 1-800-745-4447, option 3 (Monday to Friday 8 AM to 6 PM EST); Co-Pay Program 1-855-448-6520 for eligible commercial plans; Patient Assistance Program for uninsured or denied patients |
- Label dated
- August 27, 2026
- Starting dose
- 2.5 units/kg three times a week to 60 units/kg once every 2 weeks IV; titrate to disease severity and therapeutic goals.
- Dispensing gate
- No REMS. Boxed warning: initiate in a healthcare setting with monitoring and CPR equipment. Prior authorization and a site of care before the first infusion
- Required monitoring
- Supervised infusion with anaphylaxis readiness at every dose; premedicate after prior hypersensitivity; consider periodic IgG antibody monitoring during the first year; disease tests at the physician's discretion
- Example PA threshold
- Cigna example: documented deficient beta-glucocerebrosidase activity in leukocytes or fibroblasts, or biallelic pathogenic GBA variants; not for neurological manifestations; specialist prescriber; up to 60 U/kg no more than 3 times a week; no concurrent Gaucher therapy
- Support line
- CareConnect Case Managers 1-800-745-4447, option 3 (Monday to Friday 8 AM to 6 PM EST); Co-Pay Program 1-855-448-6520 for eligible commercial plans; Patient Assistance Program for uninsured or denied patients
FDA decisions for Gaucher disease
From the Trial Friend FDA decision calendar, which records each date from the sponsor's or the FDA's own announcement.
- November 25, 2026Venglustat, NDA, SanofiPending
Recent label changes
What changed in each label revision, from the FDA's approval letters and the labels' own revision lists.
- August 2026Cerezyme. DailyMed posted version 28 of the label. Its recent changes list still dates the last major changes to January 2026. FDA label
- January 2026Cerezyme. The FDA added type 3 Gaucher disease and extended type 1 use to children under 2. The label now gives infusion volumes by weight down to 1.5kg (about 3.3 lb), and requires a filter in the IV line. FDA letter
- December 2024Cerezyme. High blood pressure was added to the warnings and side effects as a possible reaction during infusions. FDA letter
- July 2024Cerezyme. The FDA added a boxed warning for severe allergic reactions, including anaphylaxis, as part of a change for enzyme replacement therapies as a group. Cerezyme must now be started in a healthcare setting with emergency equipment. FDA letter
Open trials
Questions prescribers ask about Gaucher disease
Does Cerezyme require a REMS?
No. Cerezyme has no REMS. Its prescribing guide lists what does gate the first fill and its source.
What monitoring does Cerezyme require?
Supervised infusion with anaphylaxis readiness at every dose; premedicate after prior hypersensitivity; consider periodic IgG antibody monitoring during the first year; disease tests at the physician's discretion.
What do insurers require before covering Cerezyme?
This is one public insurer policy, an example rather than every plan. Cigna example: documented deficient beta-glucocerebrosidase activity in leukocytes or fibroblasts, or biallelic pathogenic GBA variants; not for neurological manifestations; specialist prescriber; up to 60 U/kg no more than 3 times a week; no concurrent Gaucher therapy.
Which support program starts Cerezyme patients on therapy?
CareConnect Case Managers 1-800-745-4447, option 3 (Monday to Friday 8 AM to 6 PM EST); Co-Pay Program 1-855-448-6520 for eligible commercial plans; Patient Assistance Program for uninsured or denied patients.
A reference for licensed professionals, checked on November 8, 2026. Labels and plan policies change; the label on DailyMed and the plan's current policy govern. Not medical advice. For patients: the Gaucher disease page and the first 90 days pages for Cerezyme.